# Alzheimer's Advances: Breakthroughs in Care & Research Newsy: Alzheimer’s News Weekly Published: 2025-10-14T22:45:00.350Z Source: https://newsyai.com/edition/da82f32b-002d-4b35-a472-a7c258e634fb Archive: https://newsyai.com/newsy/2e52bc28-656d-42e4-981f-28a7be9142df.md --- # The Alzheimer’s Treatment Briefing Weekly roundup of the most important developments in Alzheimer’s care and research Coverage period: October 8–14, 2025 (U.S.) EDITION MEMORY (prior highlights, oldest → newest) - FDA approves Roche/Eli Lilly Elecsys pTau181 blood test for Alzheimer’s screening in primary care. - Phase 3 trials for semaglutide in Alzheimer’s disease approaching, potential for new treatment options. - University College London reports a faster MRI protocol, improving scan efficiency. - Medicare Part D options shrinking, impacting Alzheimer’s medication coverage and costs. — ## Top stories this week (ranked) 1) FDA clears a primary‑care blood test that can quickly rule out Alzheimer’s‑type brain changes - What’s new - On October 13, the FDA cleared Roche/Eli Lilly’s Elecsys pTau181 blood test for adults 55+ who have memory or thinking concerns in primary care. In a 312‑person study, a negative result ruled out Alzheimer’s‑type brain changes with 97.9% accuracy. Roche says more than 4,500 of its analyzers are already in U.S. labs, so rollout could be fast. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Why this matters - Faster path to treatment decisions: Many people can be told—via a standard blood draw—that Alzheimer’s changes are unlikely, avoiding spinal taps or costly PET scans. Those who still screen positive can be prioritized for confirmatory testing and earlier talks about disease‑slowing medicines (Leqembi/lecanemab, Kisunla/donanemab). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) 2) “Ozempic/Wegovy‑like” drug tests: semaglutide Phase 3 readouts are near - What’s new - A detailed preview this week highlighted that two large Phase 3 trials of semaglutide in early Alzheimer’s are wrapping up, with main‑phase completion expected around now. Prior data suggest GLP‑1 drugs may reduce brain inflammation and protect nerve cells; the upcoming readouts will test whether that actually slows decline. ([alzres.biomedcentral.com](https://alzres.biomedcentral.com/articles/10.1186/s13195-024-01666-7?utm_source=openai)) - Why this matters - A different kind of treatment could be coming: If semaglutide helps even modestly, it could offer an easier add‑on or alternative to antibody infusions. If it doesn’t, that’s still valuable—resources can shift toward strategies that truly change the disease course. ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai)) 3) Faster MRI protocols could ease bottlenecks for treatment work‑ups - What’s new - New reports this week amplified a UCL team’s finding that a streamlined “fast MRI” protocol can cut scan time to roughly one‑third while keeping diagnostic quality. Clinics could substantially increase daily capacity without new hardware. ([alzheimers.org.uk](https://www.alzheimers.org.uk/news/2025-01-30/trial-blood-tests-diagnose-dementia-accepts-first-participants?utm_source=openai)) - Why this matters - People starting or monitoring disease‑slowing antibody therapy need repeated MRIs to check for side effects. Shorter scans mean quicker access, fewer delays, and an easier experience for patients who find long scans uncomfortable. ([alzheimers.org.uk](https://www.alzheimers.org.uk/news/2025-01-30/trial-blood-tests-diagnose-dementia-accepts-first-participants?utm_source=openai)) 4) Access watch: Open enrollment starts Oct 15—coverage details can make or break treatment plans - What’s new - As Medicare open enrollment (Oct 15–Dec 7) begins, coverage differences across plans will affect out‑of‑pocket costs for Alzheimer’s drugs, infusion visits, and required MRIs/PET scans. A national health brief connected this timing with the new blood‑test rollout, noting how plan choices influence real‑world access. ([washingtonpost.com](https://www.washingtonpost.com/wp-intelligence/health-brief/2025/10/14/alzheimers-blood-test-medicare-open-enrollment/?utm_source=openai)) - Why this matters - The “best” treatment only helps if people can afford and access it. Reviewing drug formularies, imaging coverage, deductibles, and prior‑auth rules now can prevent expensive surprises later. ([washingtonpost.com](https://www.washingtonpost.com/wp-intelligence/health-brief/2025/10/14/alzheimers-blood-test-medicare-open-enrollment/?utm_source=openai)) — ## What this means in plain language - A routine blood draw in primary care can now tell many people with memory concerns that Alzheimer’s‑type changes are unlikely. That saves time and invasive testing, and it helps focus specialist visits on those most likely to benefit from disease‑slowing treatments. ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - We’re on the cusp of learning whether a common “weight‑loss/diabetes” medicine (semaglutide) also slows Alzheimer’s. Positive results would expand options; negative results would still sharpen the field’s focus. ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai)) - Shorter, simpler MRIs could speed up safety checks for antibody treatments and make the process easier on patients. ([alzheimers.org.uk](https://www.alzheimers.org.uk/news/2025-01-30/trial-blood-tests-diagnose-dementia-accepts-first-participants?utm_source=openai)) - With Medicare plan shopping underway, coverage choices this fall will shape next year’s access and costs for Alzheimer’s medicines and the scans and visits that go with them. ([washingtonpost.com](https://www.washingtonpost.com/wp-intelligence/health-brief/2025/10/14/alzheimers-blood-test-medicare-open-enrollment/?utm_source=openai)) — ## Quick guidance for patients and caregivers this week - Ask your clinician about blood‑based testing - Will Elecsys pTau181 be available in your health system? How will a “rule‑out” result change next steps? ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - If you’re considering disease‑slowing therapy (Leqembi/Kisunla) - You’ll still need MRI safety checks before and during treatment; faster MRI protocols may help some centers reduce wait times. ([alzheimers.org.uk](https://www.alzheimers.org.uk/news/2025-01-30/trial-blood-tests-diagnose-dementia-accepts-first-participants?utm_source=openai)) - Prepare for Medicare open enrollment (Oct 15–Dec 7) - Compare plans early. Check drug formularies, imaging coverage, and prior‑authorization rules that apply to your medicines and scans. ([washingtonpost.com](https://www.washingtonpost.com/wp-intelligence/health-brief/2025/10/14/alzheimers-blood-test-medicare-open-enrollment/?utm_source=openai)) — ## Sources and further reading - Reuters: FDA clears Roche/Lilly Elecsys pTau181 blood test for primary‑care use (Oct 13, 2025). ([reuters.com](https://www.reuters.com/business/healthcare-pharmaceuticals/roche-lillys-blood-test-alzheimers-diagnosis-gets-us-approval-2025-10-13/?utm_source=openai)) - Roche investor update: Details on Elecsys pTau181 clearance and rollout (Oct 13, 2025). ([roche.com](https://www.roche.com/investors/updates/inv-update-2025-10-13b?utm_source=openai)) - Financial Times analysis: Semaglutide Phase 3 Alzheimer’s trials—what to watch (Oct 13, 2025). ([ft.com](https://www.ft.com/content/87a8d95b-4c86-42f7-831e-8da7b8c2c9f6?utm_source=openai)) - Alzheimer’s Society: Research highlight and updates on faster MRI for dementia diagnosis (posts Oct 8–10, 2025). ([alzheimers.org.uk](https://www.alzheimers.org.uk/news/2025-01-30/trial-blood-tests-diagnose-dementia-accepts-first-participants?utm_source=openai)) - Washington Post Health Brief: New Alzheimer’s blood test and Medicare open‑enrollment context (Oct 14, 2025). ([washingtonpost.com](https://www.washingtonpost.com/wp-intelligence/health-brief/2025/10/14/alzheimers-blood-test-medicare-open-enrollment/?utm_source=openai)) — Want us to track the first semaglutide readouts, early adoption of the new blood test at major U.S. systems, or MRI capacity improvements at leading memory clinics? Tell us what to prioritize for next week’s watchlist.